drugset / Trial / NCT05722912

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

NCT05722912

Expanded access Approved for marketing Incyte Corporation

Summary

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule